VACCINE THERAPY AND/OR GM-CSF IN LOCALLY ADVANCED OR METASTATIC MELANOMA

局部晚期或转移性黑色素瘤的疫苗治疗和/或 GM-CSF

• 批准号: 7607523
• 负责人: MARK R ALBERTINI
• 金额: $ 0.08万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607523
• 关键词: Bone Marrow; Cells; Colony-Stimulating Factors; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Immune; Immune response; Institution; Metastatic Melanoma; Numbers; Patients; Peptide Vaccines; Phase III Clinical Trials; Randomized; Recruitment Activity; Recurrence; Research; Research Personnel; Resected; Resources; Somatotype; Source; Treatment Protocols; United States National Institutes of Health; Vaccine Therapy; Vaccines; Work; killings; melanoma; neoplastic cell; peripheral blood; prevent; sargramostim

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. (from ClinicalTrials.gov website) This study is no longer recruiting subjects. Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood. It is not yet known which treatment regimen is more effective for melanoma. This randomized Phase III trial is studying peptide vaccine therapy and/or sargramostim and comparing how well they work in preventing recurrences for patients with surgically resected locally advanced or surgically resected metastatic melanoma.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 (from ClinicalTrials.gov网站） 本研究不再招募受试者。 疫苗可以使身体建立免疫反应来杀死肿瘤细胞。集落刺激因子如沙格司亭增加骨髓或外周血中免疫细胞的数量。目前尚不清楚哪种治疗方案对黑色素瘤更有效。 这项随机III期试验正在研究肽疫苗疗法和/或沙格司亭，并比较它们在预防手术切除的局部晚期或手术切除的转移性黑色素瘤患者复发方面的效果。